News
August 24, 2026: Study finds black market retatrutide is not as effective as the clinical trial versions
Black market users lost an average of 4.7%, 5.3%, and 7.2% of their weight after taking “reta” for three months, six months, and one year, respectively. Those in clinical trials lost an average of 5.7%, 11.9%, and 15.5% over the same time intervals.
[...]The retatrutide black market: Patient safety groups warn of growing risks from understudied drugs
The unapproved retatrutide market holds immense safety risks, and patient safety and consumer groups are urging regulators, law enforcement, and the healthcare community to act decisively to protect Americans.
[...]August 17, 2026: Appeals court finds imported medications have “material, not theoretical” differences
The U.S. Court of Appeals for the Fourth Circuit upheld the preliminary injunction filed against alternative funding programs and related vendors, in a major win for Gilead Sciences’ civil case.
[...]He just wanted to get back to work: a simple backache ended in tragedy
35-year-old Tyreek Lewis just wanted his back pain to stop, but pain relief would mean time off from work, hours of tests, and extra appointments. So he took what looked like a simple shortcut. It killed him, and altered his family’s life forever.
[...]Statement from Partnership for Safe Medicines on new litigation alleging illegal distribution of retatrutide
Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement on the six lawsuits Eli Lilly filed today against businesses it accuses of illegally distributing unapproved copies of its investigational drug, retatrutide. Lilly is suing these defendants for illegal distribution of retatrutide including, in one case, a licensed 503A compounding pharmacy.
[...]Statement from Partnership for Safe Medicines on the appeals court’s decision in Gilead Sciences v. Meritain Health
The appeals court’s decision in Gilead Sciences v. Meritain Health is unambiguous: you cannot import untraceable medicine with foreign-language labels, hand it to American patients, and call it equivalent to an FDA-approved medicine. Track-and-trace is a cornerstone of why the U.S. drug supply chain is the safest in the world, and it is not optional.
[...]August 10, 2026: Compounded peptide injections recalled due to high endotoxin levels
Victory Medical Center Pharmacy issued a voluntary recall for three lots of its compounded glutathione vials due to elevated endotoxin levels.
[...]Key takeaways from PSM’s Axios event: Examining risk and regulation in the compounded GLP-1 landscape
SAFE Drugs Act sponsor Rep. Rudy Yakym (R-IN), Rep. Nikki Budzinski (D-IL), leading obesity medicine specialist Dr. Scott Kahan, and PSM Executive Director Shabbir Imber Safdar. delivered a clear message: Compounded substances are not the same as FDA-approved medications, and treating them as such undermines patients’ safety.
[...]August 3, 2026: Peptide vendor sentenced to six years for “incredible trail of harm”
The man was sentenced to six years for deceptively marketing “research use only” chemicals, which the judge said left “an incredible trail of harm.”
[...]PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply
PSM joined three other organizations for a sign-on letter explaining our concerns that unrestricted mass compounding increases the untraceable drug supply. An explosion of 503B compounding of these three substances, semaglutide, tirzepatide, and liraglutide, would dramatically increase the compounded medicine supply which is not serialized, and therefore, not traceable.
[...]